Clinical Trial Update: Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluated the combination of sorafenib and interferon alfa in patients with metastatic or unresectable renal cell carcinoma and has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Interferon Alfa (interferon alfa)
• Nexavar (Sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 2 | Status: COMPLETED